Focus: MeiraGTx is a New York-based gene therapy biotech focused on rare ocular and neurological diseases using AAV vectors. The company is publicly traded (MGTX) with early-stage pipeline assets across ophthalmology, neurology, and oncology indications.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net -3 jobs in 30d
2 added, 5 removed. Backfill posture.
MeiraGTx offers early-stage gene therapy exposure with public company stability, but career advancement depends entirely on clinical success with no near-term regulatory catalyst in sight.
Lead ophthalmology asset in Phase 1/2 for monogenic color blindness with unmet medical need.
Help build intelligence for MeiraGTx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MeiraGTx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Phase 1/2 program targeting inherited retinal dystrophy with significant patient population.
Only Phase 2 asset in portfolio; addresses cancer radiotherapy side effect with commercial potential beyond orphan indication.
MeiraGTx Prices $100M Offering After Reacquiring J&J Eye Drug - Hoodline
MeiraGTx Prices $100M Offering After Reacquiring J&J Eye Drug Hoodline
MeiraGTx raises $100M after reacquiring Johnson & Johnson eye drug - Crain's New York Business
MeiraGTx raises $100M after reacquiring Johnson & Johnson eye drug Crain's New York Business
8-K Filing: MeiraGTx Holdings plc (MGTX) (CIK 0001735438) — EX-10.3
EX-10.3
Eli Lilly partner MeiraGTx regains rights for genetic eye disease drug from Johnson & Johnson - MSN
Eli Lilly partner MeiraGTx regains rights for genetic eye disease drug from Johnson & Johnson MSN
Inherited blindness therapy shifts toward approval after MeiraGTx deal - Stock Titan
Inherited blindness therapy shifts toward approval after MeiraGTx deal Stock Titan
MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from J&J - BioSpace
MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from J&J BioSpace
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo